Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/10/26	$0.5600	-1.70%	362,248
07/10/26	$0.5697	+1.71%	365,535
06/10/26	$0.5601	-5.52%	328,613
05/10/26	$0.5928	+4.88%	376,089
02/10/26	$0.5652	-5.48%	237,389

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.5697USD

Average target price

20.00USD

Spread / Average Target

+3,410.62%

Consensus

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Jasper Therapeutics, Inc.

Company calendar

Market Closed - Nasdaq 23:00:00 08/10/2026 +03			5-day change	1st Jan Change
0.5600 ^USD	-1.70%		-3.45%	-69.40%

09-28	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI
09-28	Jasper Therapeutics, Inc. Announces Management Changes, Effective October 9, 2026	CI

Market Cap	18.96M 16.93M 15.79M 14.35M 26.99M 1.84B 27.26M 190M 74.16M 933M 71.17M 69.63M 3B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	18.96M 16.93M 15.79M 14.35M 26.99M 1.84B 27.26M 190M 74.16M 933M 71.17M 69.63M 3B	EV / Sales 2026 *	1.58x	EV / Sales 2027 *	-
Free-Float	97.14%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	JSPR	Delayed
CBOE	JSPR	Real-time

09-28	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI
09-28	Jasper Therapeutics, Inc. Announces Management Changes, Effective October 9, 2026	CI
09-18	Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to NASDAQ Composite Index	CI
09-15	Jasper Therapeutics, Inc. Appoints Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President	CI
08-14	Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
08-05	Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors	CI
07-17	Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026	CI
07-17	Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall	MT
07-16	Kira Pharmaceuticals acquired Jasper Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	CI
07-16	Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding	CI
06-02	Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value	CI
06-01	Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives	MT

Jasper Therapeutics, Inc. Stock

Stocks

JSPR

US4718712023

Biotechnology & Medical Research

Valuation: Jasper Therapeutics, Inc.

Chart: Jasper Therapeutics, Inc.

Latest news: Jasper Therapeutics, Inc.

Last Transcript: Jasper Therapeutics, Inc.

Analysts' recommendations: Jasper Therapeutics, Inc.

Press Releases: Jasper Therapeutics, Inc.

News in other languages: Jasper Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Jasper Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
05-15	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
05-15	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
03-23	UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25	MT
11-11	RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk	MT

10-07	Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants	AQ
09-15	Jasper Therapeutics Announces Key Regulatory and Clinical Appointments	AQ
09-09	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-17	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
08-14	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ

19/09/25	USA-Les valeurs à suivre à Wall Street (actualisé)
16/11/21	MÄRKTE USA/Kaum verändert - Zwischen China-Hoffnung und Zinssorgen
15/11/21	MÄRKTE USA/Wall Street dreht leicht ins Minus
15/11/21	MÄRKTE USA/Wall Street mit Vorschusslorbeeren für Biden-Xi-Gipfel
15/11/21	MÄRKTE USA/Wall Street vor Biden-Xi-Gipfel leicht optimistisch

1 day	-1.70%
1 week	-3.45%
Current month	-3.45%
1 month	-20.97%
3 months	+16.25%
6 months	-16.14%
Current year	-69.40%

1 week	0.54	0.62
1 month	0.54	0.73
Current year	0.32	2.07
1 year	0.32	2.69
3 years	0.32	31.01
5 years	0.32	188.8
10 years	0.32	188.8

Manager	Title	Age	Since
Jeet Mahal CEO	Chief Executive Officer	54	06/01/2026
Herbert Cross DFI	Director of Finance/CFO	54	22/09/2023
Matthew Ros COO	Chief Operating Officer	59	16/07/2026

Director	Title	Age	Since
Jeet Mahal BRD	Director/Board Member	54	06/01/2026
Judith Shizuru BRD	Director/Board Member	70	04/09/2021
Kurt von Emster BRD	Director/Board Member	59	24/09/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/31/26 A	Judith Shizuru	Free	Founder	7,500	0.0267%
7/31/26 A	Patrick Crutcher	Free	Director	7,500	0.0267%
7/31/26 A	Thomas Wiggans	Free	Chairman	7,500	0.0267%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JASPER THERAPEUTICS, INC.	-1.70%	-3.45%	-76.95%	-93.00%	18.96M
WUXI APPTEC CO., LTD.	-3.19%	-3.19%	+44.60%	+87.98%	74.68B
ARGENX SE	-15.86%	-16.67%	+3.92%	+50.90%	58.7B
LONZA GROUP AG	-2.39%	-2.05%	+4.29%	+31.33%	48.36B
REVOLUTION MEDICINES, INC.	-6.35%	-8.35%	+303.95%	+651.28%	43.05B
IQVIA HOLDINGS INC.	+0.30%	-3.71%	+28.89%	+30.33%	42.48B
BEONE MEDICINES AG	-3.82%	-4.32%	+2.49%	+101.36%	41.39B
CELLTRION, INC.	-2.13%	+1.07%	+7.51%	+50.31%	31.29B
BIONTECH SE	-3.35%	-6.35%	-13.20%	-17.22%	23.93B
INSMED INCORPORATED	-1.24%	-11.97%	-38.10%	+311.13%	22.22B
Average	-3.96%	-2.54%	+26.74%	+120.44%	38.61B
Weighted average by Cap.	-4.84%	-1.88%	+44.69%	+136.41%

	2026 *	2027 *
Net sales	12M 10.72M 10M 9.08M 17.09M 1.16B 17.25M 120M 46.94M 591M 45.06M 44.08M 1.9B	-
Net income	-	-
Net Debt	-	-